How MantaBio Is Eliminating the Costly Blind Spot of Contamination in Biopharma
An interview with Dr. Jack Regan, CEO | CTO| Co-Founder of MantaBio / As featured on the Life Sciences Decoded Podcast
|
|
Biopharmaceutical manufacturing demands precision—but when microbial contamination testing takes weeks, companies are left flying blind.
On a recent episode of Life Sciences Decoded, we sat down with Dr. Jack Regan, CEO and Co-Founder of MantaBio, a company bringing real-time visibility to one of biopharma’s biggest blind spots. Manta Bio’s fully automated, PCR-based MantaVision system delivers contamination results in just two hours, eliminating delays, preserving high-value batches, and giving manufacturers the insights they need to act fast. Based in the U.S. with a growing global presence, Manta Bio is reshaping how the industry approaches contamination control, risk mitigation, and regulatory compliance. |
Shorts
|
The Problem They Solve
|
How They Solve It
|
How Biopharma Wants to Use It
|
Inspired by this story? Tell us yours!
We feature innovators shaping the future of biotech, diagnostics, and healthcare. If that’s you, let’s talk.
|
|
Topics We Cover
|